Anti-cancer drug development & formulation news
Curated headlines on oncology formulations, injectables, biosimilars and manufacturing — aggregated from leading global pharmaceutical publications and refreshed continuously.
Live feed · updated hourly from global industry sources
What real-world data shows about current cancer care
Only about 5% of adult cancer patients join clinical trials. Experts explain how real-world data fills gaps and what makes it representative and reliable. The post What real-world data shows about current cancer care …
Read full articleRoche picks cancer targets, Hansoh builds the ADCs in deal with $400 million upfront
Roche picks the targets and Hansoh builds the ADCs under a deal with $400 million upfront, a $110 million first-anniversary payment and more than $15 billion in milestones. The split mirrors AstraZeneca’s January deal…
Read moreAfter decades of trial failures in chemotherapy-linked neuropathy, psilocybin shows promise in preventing it in mice
The magic mushroom compound psilocybin, which has had favorable results in two Phase 3 trials of depression and could be available as soon as 2027, has shown promise in rodents as a potential preventative for Chemothe…
Read moreCancer vaccine borrows COVID immune memory to activate T cells against tumors in mice
The COVID-19 pandemic left most of the world’s population with an immune memory for COVID. A Cleveland-based biotech wants to use that memory to fight cancer. Celloram, a preclinical stage company focusing on therapie…
Read moreMerck and Moderna’s cancer vaccine is customized for each patient’s tumor
A new investigational cancer vaccine developed by Merck & Co. and Moderna is customized based on the genome of each patient’s tumor, designed to teach their immune system to recognize the cancer as a foreign body. The…
Read moreHeadlines are aggregated from third-party publications and link to their original sources. Salus Pharmaceuticals is not affiliated with these outlets.